Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · MANKIND

MANKIND

HealthcarePharmaceuticals & Biotechnology₹108424 cr market cap
₹2629.00 ▲ +0.15% today As of 19 Nov 2026
52-week low ₹1927.4052-week high ₹2668.30

-1.6% from the 52-week high · +36.2% above the low

Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. The company is headquartered in New Delhi, Delhi and currently employs 18,468 full-time employees. The company went IPO on 2023-05-09. The firm is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.

The short version. MANKIND reported revenue of ₹4,338 crore for Sep 2026, up 17.3% from a year earlier. Net profit was ₹711 crore (up 38.9% year on year). Return on equity was 11.7% in Mar 2026. Promoter holding was 72.62% in Sep 2026, down 0.09 points over 8 quarters.

1 · The price

How has the stock traded?

MANKIND trades 1.6% below its 52-week high and 36.2% above its 52-week low.

Change over period: —

1M+16.5%
3M+9.6%
6M+1.6%
1Y+17.9%

2 · The business

Is it growing?

Sales, year on year+17.3%

Sep 2026 revenue of ₹4,338 cr.

Profit, year on year+38.9%

Sep 2026 net profit of ₹711 cr.

Net margin16.4%

2.6 pts higher than a year earlier.

3-year growth14.3% profit

Revenue compounded at 18.1% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue43384031344335673697357030793230
Net profit711574554409512438421380
Net margin %16.414.216.111.513.812.313.711.8
EPS (₹)17.2313.913.439.912.3910.6210.29.22

Annual

FY2026FY2025FY2024FY2023
Revenue1427812207103358749
Net profit1913199119131282
Net margin %13.416.318.514.7
EPS (₹)46.3448.2647.7532.0

3 · The quality

How well does it turn capital into profit?

Return on equity was 11.7% in Mar 2026; debt to equity is 0.39.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %11.713.920.417.2
Return on capital %13.713.324.621.7
EBITDA margin %26.327.926.522.9
Net margin %13.115.618.014.4

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR18.1%—
Profit CAGR14.3%—
Debt to equity0.39
Interest cover4.6x
Current ratio1.10
P/E ratio48.6

4 · The owners

Who holds it, and are they adding?

Promoter holding72.62%

Down 0.09 pts over 8 quarters.

Foreign institutions9.37%

Down 3.97 pts over 8 quarters.

Domestic institutions15.56%

Up 4.5 pts over 8 quarters.

Mutual fund schemes244

+61 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter72.7172.772.6872.6772.6672.6672.6372.62-0.09
FII13.3412.9213.0712.8411.3410.249.459.37-3.97
DII11.0611.4811.511.9213.2514.4615.3915.56+4.5
Public2.92.92.752.572.752.642.532.45-0.45

Mutual fund holdings · Oct 2026

244 schemes hold this stock

183 the month before.

  • ICICI Prudential Healthcare Fund4.5% of NAV
  • EDELWEISS FOCUSED FUND4.47% of NAV
  • NIPPON INDIA PHARMA FUND4.4% of NAV
  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND4.26% of NAV
  • Motilal Oswal Nifty MidSmall Healthcare Index Fund4.25% of NAV
  • PGIM INDIA HEALTHCARE FUND3.95% of NAV
  • Motilal Oswal Innovation Opportunities Fund3.88% of NAV
  • ITI Pharma and Healthcare Fund3.75% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for MANKIND are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about MANKIND

What is the MANKIND share price?

MANKIND (MANKIND) last closed at ₹2,629.00, up 0.15% on the day. Its 52-week range is ₹1,927.40 to ₹2,668.30.

What is the market cap of MANKIND?

MANKIND has a market capitalisation of about ₹108,424 crore. Its price-to-earnings ratio is 48.6.

How are MANKIND's latest results?

MANKIND reported revenue of ₹4,338 crore for Sep 2026, up 17.3% from a year earlier. Net profit was ₹711 crore (up 38.9% year on year). Return on equity was 11.7% in Mar 2026. Promoter holding was 72.62% in Sep 2026, down 0.09 points over 8 quarters.

Who owns MANKIND?

As of Sep 2026, shareholding was: Promoter 72.62%, FII 9.37%, DII 15.56%, Public 2.45%.

How many mutual funds hold MANKIND?

244 mutual fund schemes held MANKIND in October 2026. That compares with 183 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 08 Aug 2025 · Interim Dividend - Rs. 1

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.